COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report

Mauro Bertolini1, María Felicitas Mutti1, José AE Barletta1, Adriana Falak1, Daniel Cuatz1, Alicia Sisto1, Martin A Ragusa2, Nigel Osvaldo Fernandez Claros2 and María José Rolón1

Abstract
Limited information is available concerning the coexistence of COVID-19 and opportunistic infections in people living with HIV. The possible association of COVID-19 with AIDS-related respiratory diseases should be considered, particularly in patients with advance immunosuppression. We report the case of a male patient with AIDS-related disseminated histoplasmosis associated with COVID-19.

Keywords
HIV, AIDS, COVID-19, histoplasmosis, opportunistic infections

Date received: 2 June 2020; accepted: 18 August 2020

Introduction
While universal antiretroviral therapy (ART) is recommended by the World Health Organization (WHO)1 to all people living with HIV (PLHIV), regardless of their immune status, only 60% of PLHIV receive sustained ART worldwide2; and opportunistic infections (OIs) continue to cause significant morbidity and mortality, particularly in low- and middle-income countries.1

Disseminated histoplasmosis (DH) is caused by the dimorphic fungus Histoplasma capsulatum, endemic to the central and south-central United States and to Latin America. In these areas, the annual incidence rate may approach 5% among PLHIV,3 affecting particularly individuals with CD4 count <150 cells/mm3.1

Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).4 On March 11, 2020, COVID-19 was defined as a pandemic by the WHO.5 It is not entirely clear how PLHIV are affected by COVID-19, particularly in the setting of profound AIDS-related immunosuppression and coexistence with HIV-related OIs. We report the case of a male patient presenting with AIDS-related DH associated with COVID-19.

Case report
A 43-year-old man with a history of HIV infection and poor adherence to ART presented with cough and dyspnea of acute onset, associated with fever, night sweats, abdominal pain and diarrhea of 1-month duration. Physical examination revealed hypoxemia (pulse oximetry on room air was 93%) and generalized ulcerated skin lesions, as well as bilateral cervical, supraclavicular and inguinal tender adenopathies, oral thrush and hepatomegaly. Generalized hypoventilation and diffuse crackles were found on respiratory examination. Laboratory tests showed ferritin 1500 ng/mL (normal...
range: 23.9–336.2 ng/mL), D-dimer 431 ng/mL (normal range: <230 ng/mL), C-reactive protein 16 mg/dL (normal range <1.0 mg/dL), LDH 380 U/L (normal range 120–246 U/L), mild transaminitis and a white blood cell count within normal range except for mild lymphopenia. CD4 cell count was 16.3 cells/mm³ (3.7%). Chest CT scan demonstrated miliary-pattern infiltrates and bilateral peripheral multifocal ground-glass opacities (Figure 1).

Skin lesion scarification was carried out, with Giemsa staining evidencing the presence of *Histoplasma capsulatum*-like intracellular yeasts. Due to local circulation of COVID-19, SARS-CoV-2 RT-PCR was performed on a nasopharyngeal swab sample collected from the patient and he was admitted to the hospital with a diagnosis of DH. Since liposomal amphotericin was not available, treatment with intravenous amphotericin B deoxycholate at 1 mg/kg/day was administered. The patient remained hemodynamically stable and his oxygen requirements decreased during the course of follow-up. Forty-eight hours after the patient’s admission, his skin culture and lysis-centrifugation blood culture grew *H. capsulatum* and a detectable SARS-CoV-2 RT-PCR result was obtained from the sample taken at hospital admission (amplifying sequences from N-gene and E-gene, with a cycle threshold [Ct] of 36). Although lopinavir/ritonavir and hydroxychloroquine were considered as possible off-label treatments for COVID-19 at the time,7,8 due to concerns about potential toxicity and drug-drug interactions with antifungal therapy, and since the patient’s clinical status had improved significantly, we decided to withhold the specific treatment of SARS-CoV-2.

The clinical course was favorable. After one week of hospitalization and being afebrile for 48 hours, the patient had a new nasopharyngeal swab sample taken and this time the SARS-CoV-2 virus was not detected with RT-PCR. The antifungal therapy was switched to itraconazole (200 mg PO TID for 3 days, then 200 mg PO BID) after 14 days of intravenous treatment and ART was re-started with tenofovir disoproxil fumarate/emtricitabine plus dolutegravir. The patient was subsequently discharged and then, lost to follow up.

**Discussion**

Even though limited data are available regarding the clinical course and prognosis of COVID-19 in PLHIV, this population does not seem to be disproportionately affected by it, in terms of incidence or frequency of severe disease.9,10 Nevertheless, recent studies have shown higher risk of death from COVID-19 in PLHIV, irrespective of viral suppression.11 It should be noted that in the case of PLHIV with advanced disease and profound immunosuppression, COVID-19 may coexist with other AIDS-related conditions, including respiratory OI,5 which could lead to difficulties in diagnosis, clinical course, patient management and increased morbidity and mortality.

It has been hypothesized that immunosuppressed patients may have prolonged SARS-CoV-2 viral shedding.12,13 However, our patient showed what appears to be a rapid viral clearance in his upper respiratory tract, even in the absence of specific treatment; but since the symptoms of histoplasmosis could have overlapped with those related to COVID-19, the exact date of COVID-19-related symptoms onset could not be precisely defined; therefore, DH may have appeared during the resolution of the previous COVID-19 infection.
Conclusion
To the best of our knowledge, this is the first case of COVID-19 presenting with AIDS-related DH, reported in the medical literature so far. The possible association of COVID-19 with respiratory OI should be strongly considered in patients with advanced immunosuppression, particularly in areas significantly affected by the pandemic. Further research regarding epidemiology, clinical features, prognosis of COVID-19 in PLHIV and possible association with AIDS-related OI is warranted.

Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Mauro Bertolini https://orcid.org/0000-0002-9038-0785
José AE Barletta https://orcid.org/0000-0003-2210-5965
Martín A Ragusa https://orcid.org/0000-0002-3182-8041

References
1. UNAIDS 2014 90-90-90. An ambitious treatment target to help end the AIDS epidemic, www.unaids.org/en/resources/documents/2017/90-90-90 (accessed 1 June 2020).
2. UNAIDS. 90-90-90: treatment for all, www.unaids.org/en/resources/909090 (accessed 1 June 2020).
3. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oii.pdf (accessed 7 May 2020).
4. The International AIDS Society. COVID-19 and HIV: what you need to know, www.iasociety.org/covid-19-hiv (accessed 1 June 2020).
5. Tedros Adhanom Ghebreyesus. WHO Director-General’s opening remarks at the media briefing on COVID-19 - March 11, 2020, https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020 (2020, accessed 1 June 2020).
6. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases, https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&isAllowed=y (accessed 30 July 2020).
7. Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252–256.
8. Colson P, Rolain J-M, Lagier J-C, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55: 105932.
9. US Department of Health and Human Services. Interim guidance for COVID-19 and persons with HIV, https://aidsinfo.nih.gov/guidelines/html/8/covid-19-and-persons-with-hiv-interim-guidance-554/interim-guidance-for-covid-19-and-persons-with-hiv (accessed 1 June 2020).
10. Vizcarra P, Pérez-Elias MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. The Lancet HIV, https://www.thelancet.com/journals/lancetissue/issue/vol7no8/PIIS2352-3018(20)X0008-7 VOLUME 7, ISSUE 8, E554–E564, AUGUST 01, 2020. DOI: https://doi.org/10.1016/S2352-3018(20)30164-8.
11. Mary-Ann Davies. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa. Western Cape Department of Health with National Institute for Communicable Diseases, South Africa medRxiv 2020.07.02.20145185; doi: https://doi.org/10.1101/2020.07.02.20145185.
12. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients, Clinical Infectious Diseases, ciaa460, https://doi.org/10.1093/cid/ciaa460.
13. Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China, European Urology, Volume 77, Issue 6, 2020, Pages 748754, ISSN 0302-2838, https://doi.org/10.1016/j.eururo.2020.03.039.